| Identification | Back Directory | [Name]
1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)-β,δ-dihydroxy-4-[[[4-(hydroxymethyl)phenyl]amino]carbonyl]-5-(1-methylethyl)-3-phenyl-, (βR,δR)- | [CAS]
805241-79-6 | [Synonyms]
PPD10558
RBx10558
RBx-10558
PPD-10558
RBx 10558
PPD 10558
1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)-β,δ-dihydroxy-4-[[[4-(hydroxymethyl)phenyl]amino]carbonyl]-5-(1-methylethyl)-3-phenyl-, (βR,δR)- | [Molecular Formula]
C34H37FN2O6 | [MOL File]
805241-79-6.mol | [Molecular Weight]
588.68 |
| Chemical Properties | Back Directory | [Boiling point ]
769.1±60.0 °C(Predicted) | [density ]
1.26±0.1 g/cm3(Predicted) | [form ]
Solid | [pka]
4.29±0.10(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
Bemfivastatin (PPD 10558) is an orally active, HMG-CoA Reductase (HMGCR) inhibitor, also known as Statin. Bemfivastatin enhances the activity of liver extraction. Bemfivastatin exhibits little developmental toxicity effects in pregnant rats and rabbits via daily oral doses during organogenesis period. The no observed adverse effect level (NOAEL) are ≥320?mg/kg/day for rats developmental toxicity, 12.5?mg/kg/day for rabbits maternal toxicity, and 25?mg/kg/day for rabbits developmental toxicity, respectively. Bemfivastatin can be used for research on Statin-related hypercholesterolemic myalgia with inability to tolerate statins[1][2]. | [References]
[1] Faqi AS, et al. Developmental toxicity of the HMG-CoA reductase inhibitor (PPD10558) in rats and rabbits. Birth Defects Res B Dev Reprod Toxicol. 2012 Feb;95(1):23-37. DOI:10.1002/bdrb.20337
[2] Wierzbicki A, et al. Drugs in development for the management of dyslipidaemia[J]. Future Prescriber, 2012, 13(2): 12-15. |
|
|